Tandem Diabetes Care (TNDM) EBIT (2013 - 2026)

Tandem Diabetes Care has reported EBIT for 14 years, with the latest figure at -$17.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 85.58% year-over-year to -$17.4 million; the trailing twelve-month figure through Mar 2026 stood at -$83.8 million (up 53.0% YoY), and the FY2025 full-year result was -$187.3 million, down 88.91% from the prior year.
• EBIT for Q1 2026 stood at -$17.4 million, down from $8.3 million in the prior quarter.
• The five-year high for EBIT was $8.3 million in Q4 2025, with the low at -$127.8 million in Q1 2023.
• Historically, EBIT has averaged -$37.1 million across 5 years, with a median of -$30.8 million in 2024.
• Annual changes were most pronounced in 2023 — EBIT sank 733.34% — and 2025, when it soared 1527.54%.
• Tandem Diabetes Care's EBIT stood at -$17.8 million in 2022, then plunged by 97.22% to -$35.1 million in 2023, then surged by 98.34% to -$581000.0 in 2024, then soared by 1527.54% to $8.3 million in 2025, then tumbled by 310.2% to -$17.4 million in 2026.
• The last three EBIT figures came in at -$17.4 million (Q1 2026), $8.3 million (Q4 2025), and -$22.9 million (Q3 2025), per Business Quant data.